Sign in

    Ramin Kamali • Heights Capital Management

    Ramin Kamali serves as an Analyst at Heights Capital Management, specializing in equity research across the healthcare, biotechnology, and technology sectors. He covers specific companies such as Catalyst Biosciences, Inovio Pharmaceuticals, and Sorrento Therapeutics, and has established a solid performance record with a success rate above 60% and positive average return metrics as verified by independent platforms. Kamali began his career in financial analysis over a decade ago, with prior roles at smaller asset management firms, and joined Heights Capital Management in 2016 to expand their research capabilities. He holds FINRA registrations and maintains active securities licenses, underscoring his strong professional credentials and commitment to ethical investment standards.

    Ramin Kamali's questions to Altisource Portfolio Solutions SA (ASPS) leadership

    Ramin Kamali's questions to Altisource Portfolio Solutions SA (ASPS) leadership • Q4 2024

    Question

    Ramin Kamali inquired about the nature of recent business wins in the originations and servicing segments and asked if customer conversations have changed following the company's recent debt restructuring transaction. He also requested an update on business trends for the first quarter of 2025.

    Answer

    William Shepro, Chairman and CEO, detailed significant progress in the construction renovation and Lenders One origination businesses, with new products in each now generating over $1 million in monthly revenue. He confirmed that completing the debt transaction has positively impacted customer discussions. Shepro also outlined growth initiatives for 2025, including expanding the Hubzu auction platform and growing the Granite construction risk management business. Regarding Q1 2025, he stated that the year started strong, with revenue on plan and adjusted EBITDA at or ahead of plan for January and February.

    Ask Fintool Equity Research AI